
  
    
      
        
        For_IN half_PDT a_DT century_NN ,_, natural_JJ products_NNS from_IN microorganisms_NNS have_VBP been_VBN the_DT main_JJ source_NN of_IN
        medicines_NNS for_IN treating_VBG infectious_JJ disease_NN ._. The_DT most_RBS important_JJ chemical_NN class_NN of_IN these_DT
        antibiotics_NNS ,_, apart_RB from_IN the_DT penicillins_NNS ,_, is_VBZ the_DT polyketides_NNS ._. They_PRP are_VBP made_VBN by_IN the_DT stepwise_NN
        building_NN of_IN long_JJ carbon_NN chains_NNS ,_, two_CD atoms_NNS at_IN a_DT time_NN ,_, by_IN multifunctional_NN enzymes_NNS that_WDT
        determine_VBP the_DT chain_NN length_NN ,_, oxidation_NN state_NN ,_, and_CC pattern_NN of_IN branching_VBG ,_, cyclisation_NN ,_, and_CC
        stereochemistry_NN of_IN the_DT molecules_NNS in_IN a_DT combinatorial_NN fashion_NN to_TO produce_VB an_DT enormous_JJ variety_NN
        of_IN structures_NNS ._. Recent_JJ elucidation_NN of_IN the_DT genetic_JJ ‘ programming_NN’ of_IN the_DT enzymes_NNS has_VBZ opened_VBN a_DT
        new_JJ field_NN of_IN drug_NN discovery_NN based_VBN on_IN rationally_RB engineering_VBG the_DT enzymes_NNS to_TO produce_VB
        ‘ unnatural_NN natural_JJ products_NNS’ with_IN novel_NN properties_NNS ._.
        Following_VBG the_DT development_NN of_IN penicillin_NN for_IN the_DT treatment_NN of_IN septicemia_NN in_IN the_DT early_JJ
        1940_CD s_VBZ ,_, numerous_JJ antibiotics_NNS were_VBD discovered_VBN and_CC introduced_VBN into_IN medicine_NN ._. While_IN a_DT fungus_NN
        makes_VBZ penicillin_NN ,_, semisynthetic_JJ derivatives_NNS of_IN which_WDT have_VBP been_VBN a_DT mainstay_NN of_IN antibacterial_NN
        therapy_NN for_IN decades_NNS ,_, most_RBS natural_JJ antibacterial_NN antibiotics_NNS come_VBP from_IN a_DT group_NN of_IN
        soil-dwelling_JJ ,_, filamentous_JJ bacteria_NNS called_VBD the_DT actinomycetes_NNS ,_, of_IN which_WDT 
        Streptomyces_NNP is_VBZ the_DT best-known_JJS genus_JJ ._. These_DT organisms_NNS make_VBP an_DT
        amazing_JJ array_NN of_IN so-called_JJ secondary_JJ metabolites_NNS that_WDT have_VBP evolved_VBN to_TO give_VB their_PRP$ producers_NNS
        a_DT competitive_JJ advantage_NN in_IN the_DT complex_JJ soil_NN environment_NN ,_, where_WRB they_PRP are_VBP exposed_VBN to_TO stresses_NNS
        of_IN all_DT kinds_NNS (_( Challis_NNP and_CC Hopwood_NNP 2003_CD )_) ._. The_DT compounds_NNS have_VBP many_JJ functions_NNS ,_, but_CC those_DT with_IN
        antibiotic_JJ activity_NN are_VBP the_DT most_RBS important_JJ from_IN the_DT human_JJ perspective_NN ._. Actinomycete_NNP
        antibiotics_NNS include_VBP such_JJ antibacterial_NN compounds_NNS as_IN tetracycline_NN and_CC erythromycin_NN ,_,
        antifungal_NN agents_NNS like_IN candicidin_NN and_CC amphotericin_NN ,_, anticancer_NN drugs_NNS such_JJ as_IN doxorubicin_NN ,_,
        and_CC the_DT antiparasitic_JJ avermectin_NN (_( Walsh_NNP 2003_CD )_) ._.
        While_IN many_JJ different_JJ chemical_NN classes_NNS are_VBP represented_VBN amongst_IN actinomycete_NN antibiotics_NNS ,_,
        one_CD class_NN accounts_NNS for_IN an_DT extraordinary_JJ proportion_NN of_IN the_DT important_JJ compounds_NNS ,_, including_VBG
        all_PDT those_DT mentioned_VBN above_IN ._. This_DT chemical_NN family_NN is_VBZ made_VBN up_RP of_IN the_DT polyketides_NNS ._. They_PRP are_VBP
        synthesized_JJ by_IN multifunctional_NN enzymes_NNS called_VBD polyketide_NN synthases_NNS (_( PKSs_NNP )_) ,_, which_WDT are_VBP
        related_VBN to_TO the_DT fatty_NN acid_NN synthases_NNS that_WDT make_VBP the_DT lipids_NNS essential_JJ for_IN the_DT integrity_NN of_IN
        cell_NN membranes_NNS ,_, but_CC they_PRP carry_VBP out_IN much_RB more_RBR complex_JJ biosynthetic_JJ routines_NNS ._. Repeated_NNP rounds_NNS
        of_IN carbon_NN chain_NN building_NN and_CC modification_NN use_NN a_DT series_NN of_IN independently_RB variable_JJ reactions_NNS
        selected_VBD according_VBG to_TO a_DT ‘ program_NN’ characteristic_NN of_IN each_DT PKS_NNP (_( Reeves_NNP 2003_CD )_) ._. Recent_JJ research_NN
        has_VBZ focused_VBN on_IN determining_VBG this_DT program_NN so_RB as_IN to_TO be_VB able_JJ to_TO modify_VB it_PRP in_IN rational_JJ ways_NNS by_IN
        genetic_JJ engineering_NN and_CC thus_RB generate_VB novel_NN drug_NN candidates_NNS ._. The_DT resulting_VBG field_NN of_IN
        ‘ combinatorial_NN biosynthesis_NNS’ of_IN ‘ unnatural_NN natural_JJ products_NNS’ has_VBZ been_VBN given_VBN added_VBN urgency_NN
        by_IN the_DT rise_NN of_IN multidrug-resistant_JJ pathogens_NNS ,_, of_IN which_WDT MRSA_NNP (_( methicillin-resistant_JJ 
        Staphylococcus_NNP aureus_NN )_) is_VBZ simply_RB the_DT most_RBS discussed_VBN of_IN a_DT series_NN
        of_IN threats_NNS (_( Walsh_NNP 2003_CD )_) ._. How_WRB do_VBP PKSs_NNP work_NN and_CC how_WRB can_MD we_PRP make_VB new_JJ ones_NNS ?_.
      
      
        Molecular_NNP Diversity_NNP
        The_DT heart_NN of_IN PKS_NNP function_NN is_VBZ the_DT synthesis_NN of_IN long_JJ chains_NNS of_IN carbon_NN atoms_NNS by_IN joining_VBG
        (_( condensing_VBG )_) together_RB small_JJ organic_JJ acids_NNS ,_, such_JJ as_IN acetic_JJ and_CC malonic_JJ acid_NN ,_, by_IN a_DT so-called_JJ
        ketosynthase_NN function_NN ._. This_DT uses_VBZ the_DT building_NN units_NNS in_IN the_DT form_NN of_IN activated_VBN derivatives_NNS ,_,
        called_VBN coenzyme_NN A_DT (_( CoA_NNP )_) esters_NNS ,_, so_IN we_PRP speak_VBP of_IN acetyl-_NN CoA_NNP and_CC malonyl-_NN CoA_NNP ,_, for_IN example_NN ._. The_DT
        special_JJ form_NN of_IN condensation_NN that_WDT joins_VBZ them_PRP is_VBZ driven_VBN by_IN loss_NN of_IN carbon_NN dioxide_NN ._. Thus_RB ,_,
        when_WRB acetyl-_NN CoA_NNP ,_, with_IN two_CD carbon_NN atoms_NNS ,_, joins_VBZ with_IN malonyl-_NN CoA_NNP ,_, with_IN three_CD carbons_NNS ,_, one_CD of_IN
        the_DT latter_NN is_VBZ lost_VBN and_CC a_DT chain_NN of_IN four_CD carbon_NN atoms_NNS results_NNS (_( Figure_NN 1_CD A_DT )_) ._. Further_RB rounds_NNS of_IN
        condensation_NN extend_VBP the_DT chain_NN by_IN two_CD carbons_NNS at_IN each_DT step_NN ._. If_IN the_DT chain-extender_JJ unit_NN ,_,
        instead_RB of_IN being_VBG malonyl-_NN CoA_NNP ,_, is_VBZ methylmalonyl-_NN CoA_NNP ,_, which_WDT has_VBZ four_CD carbon_NN atoms_NNS ,_, the_DT linear_JJ
        carbon_NN chain_NN is_VBZ still_RB extended_VBN by_IN two_CD carbons_NNS ,_, and_CC the_DT ‘ extra_JJ’ carbon_NN forms_VBZ a_DT methyl_NN side_NN
        branch_NN ._. More_RBR complex_JJ extender_NN units_NNS produce_VBP more_RBR complex_JJ side_NN branches_NNS ._.
        Choices_NNS of_IN the_DT number_NN and_CC type_NN of_IN the_DT building_NN units_NNS are_VBP variables_NNS in_IN determining_VBG
        polyketide_NN structure_NN ._. Another_DT concerns_VBZ the_DT keto_NN groups_NNS (_( C_NNP =_SYM O_NNP )_) that_WDT appear_VBP at_IN every_DT alternate_JJ
        carbon_NN atom_NN in_IN the_DT growing_VBG chain_NN as_IN a_DT result_NN of_IN the_DT condensation_NN process_NN (_( accounting_NN for_IN
        the_DT name_NN polyketide_NN )_) ._. They_PRP may_MD remain_VB intact_JJ ._. Alternatively_RB ,_, some_DT may_MD be_VB modified_VBN or_CC
        removed_VBN by_IN a_DT series_NN of_IN three_CD steps_NNS (_( Figure_NN 1_CD B_NNP )_) ,_, any_DT of_IN which_WDT may_MD be_VB omitted_VBN ._. This_DT results_NNS
        in_IN keto_NN groups_NNS remaining_VBG at_IN some_DT points_NNS in_IN the_DT chain_NN ;_: hydroxyl_NN groups_NNS (_( –_NN OH_NNP )_) ,_, formed_VBN by_IN
        reduction_NN of_IN a_DT keto_NN group_NN ,_, at_IN others_NNS ;_: double_JJ bonds_NNS between_IN some_DT adjacent_JJ carbon_NN atoms_NNS ,_,
        resulting_VBG from_IN removal_NN of_IN the_DT hydroxyl_NN by_IN loss_NN of_IN water_NN (_( dehydration_NN )_) ;_: or_CC full_JJ saturation_NN
        with_IN hydrogen_NN atoms_NNS elsewhere_RB ,_, arising_VBG by_IN ‘ enoyl_NN’ reduction_NN of_IN the_DT double_JJ bond_NN (_( Figure_NN 1_CD C_NNP )_) ._.
        A_DT further_JJ variable_JJ concerns_VBZ the_DT stereochemistry_NN of_IN the_DT hydroxyl_NN groups_NNS and_CC methyl_NN or_CC other_JJ
        carbon_NN branches_NNS ,_, each_DT of_IN which_WDT can_MD exist_VB in_IN two_CD possible_JJ configurations_NNS ._. Finally_RB ,_, the_DT
        nascent_NN carbon_NN chain_NN adopts_VBZ different_JJ folding_NN patterns_NNS after_IN it_PRP leaves_VBZ the_DT PKS_NNP ,_, and_CC
        ‘ tailoring_VBG’ enzymes_NNS can_MD then_RB add_VB sugars_NNS or_CC other_JJ chemical_NN groups_NNS to_TO it_PRP at_IN many_JJ alternative_JJ
        positions_NNS ,_, enabled_VBN by_IN the_DT pattern_NN of_IN chemical_NN reactivity_NN built_VBN into_IN the_DT polyketide_NN by_IN the_DT
        PKS_NNP ._. The_DT challenge_NN has_VBZ been_VBN to_TO understand_VB the_DT programming_NN of_IN the_DT PKS_NNP that_IN accounts_NNS for_IN this_DT
        gamut_NN of_IN structural_JJ variation_NN ._.
        During_IN the_DT 1990_CD s_VBZ ,_, the_DT ability_NN to_TO manipulate_VB actinomycete_NN genes_NNS ,_, developed_VBN over_IN previous_JJ
        decades_NNS ,_, mainly_RB using_VBG the_DT model_NN species_NNS 
        Streptomyces_NNP coelicolor_NN (_( Hopwood_NNP 1999_CD )_) ,_, was_VBD combined_VBN with_IN
        chemical_NN and_CC biochemical_JJ experiments_NNS to_TO begin_VB to_TO crack_VB this_DT ‘ polyketide_NN code_NN’ ._. The_DT first_JJ
        studies_NNS were_VBD on_IN organisms_NNS making_VBG antibiotics_NNS of_IN the_DT ‘ aromatic_JJ’ family_NN ,_, which_WDT includes_VBZ
        tetracycline_NN and_CC doxorubicin_NN ,_, as_RB well_RB as_IN the_DT model_NN compounds_NNS actinorhodin_NN (_( made_VBN by_IN 
        S_NNP ._. coelicolor_NN itself_PRP )_) and_CC tetracenomycin_NN ._. The_DT main_JJ variable_NN in_IN
        their_PRP$ structure_NN is_VBZ carbon_NN chain_NN length_NN ,_, with_IN few_JJ choices_NNS of_IN different_JJ building_NN units_NNS or_CC
        keto_NN group_NN modification_NN ,_, so_IN the_DT programming_NN would_MD (_( in_IN principle_NN )_) be_VB simple_JJ ._. The_DT DNA_NNP
        sequences_NNS responsible_JJ for_IN such_JJ PKSs_NNP revealed_VBD sets_NNS of_IN genes_NNS encoding_VBG proteins_NNS ,_, including_VBG
        ketosynthases_NNS ,_, ketoreductases_NNS ,_, and_CC acyl_NN carrier_NN proteins_NNS (_( ACPs_NNP )_) (_( the_DT unit_NN of_IN the_DT PKS_NNP on_IN
        which_WDT the_DT growing_VBG carbon_NN chain_NN is_VBZ tethered_VBN ;_: see_VB Figure_NN 1_CD A_DT )_) ,_, that_WDT would_MD come_VB together_RB to_TO
        form_VB a_DT multicomponent_NN PKS_NNP resembling_VBG a_DT typical_JJ bacterial_JJ fatty_NN acid_NN synthase_NN ._. In_IN contrast_NN ,_,
        the_DT DNA_NNP sequence_NN of_IN the_DT gene_NN set_VBN for_IN the_DT complex_JJ polyketide_NN erythromycin_NN ,_, made_VBN by_IN a_DT
        relative_NN of_IN 
        Streptomyces_NNP called_VBN 
        Saccharopolyspora_NNP erythraea_NN ,_, which_WDT has_VBZ more_RBR involved_JJ
        programming_NN ,_, revealed_VBD multifunctional_NN proteins_NNS with_IN the_DT various_JJ enzymic_JJ functions_NNS carried_VBD
        out_IN by_IN active_JJ sites_NNS on_IN the_DT same_JJ polypeptide_NN chain_NN ,_, as_IN in_IN a_DT mammalian_JJ fatty_NN acid_NN
        synthase_NN ._.
        The_DT big_JJ surprise_NN ,_, though_RB ,_, was_VBD the_DT finding_NN of_IN six_CD sets_NNS ,_, or_CC modules_NNS ,_, of_IN such_JJ active_JJ sites_NNS ,_,
        corresponding_JJ to_TO the_DT six_CD rounds_NNS of_IN condensation_NN needed_VBN to_TO build_VB the_DT carbon_NN chain_NN (_( Cortes_NNP et_CC
        al_NN ._. 1990_CD ;_: Donadio_NNP et_CC al_NN ._. 1991_CD )_) ._. The_DT modules_NNS each_DT contain_VB an_DT acyl_NN transferase_NN (_( to_TO load_VB the_DT
        extender_NN unit_NN onto_IN the_DT enzyme_NN )_) ,_, as_RB well_RB as_IN a_DT ketosynthase_NN and_CC an_DT ACP_NNP domain_NN ,_, together_RB with_IN
        exactly_RB those_DT reductive_JJ activities_NNS needed_VBN to_TO generate_VB the_DT required_JJ pattern_NN of_IN modification_NN
        of_IN the_DT chain_NN at_IN each_DT step_NN of_IN elongation_NN ._. Thus_RB was_VBD born_VBN an_DT ‘ assembly_NN line_NN’ model_NN in_IN which_WDT
        the_DT program_NN for_IN the_DT PKS_NNP is_VBZ hardwired_JJ into_IN the_DT DNA_NNP and_CC expressed_VBD in_IN a_DT linear_JJ array_NN of_IN active_JJ
        sites_NNS (_( domains_NNS )_) along_IN the_DT giant_JJ protein_NN ._. This_DT consists_VBZ of_IN the_DT six_CD chain-building_JJ modules_NNS ,_,
        preceded_VBN by_IN a_DT short_JJ module_NN for_IN loading_VBG the_DT starter_JJ unit_NN and_CC ending_VBG in_IN a_DT domain_NN for_IN
        releasing_VBG the_DT completed_VBN carbon_NN chain_NN from_IN the_DT PKS_NNP ._. The_DT carbon_NN chain_NN of_IN the_DT polyketide_NN would_MD
        be_VB assembled_VBN and_CC modified_VBN progressively_RB as_IN the_DT molecule_NN moved_VBD along_IN the_DT protein_NN ,_,
        interacting_VBG with_IN each_DT domain_NN in_IN turn_NN ,_, which_WDT would_MD select_VB extender_NN units_NNS ,_, make_VB carbon–carbon_NN
        bonds_NNS ,_, and_CC modify_VB keto_NN groups_NNS as_IN appropriate_JJ ,_, depending_VBG on_IN the_DT presence_NN or_CC absence_NN of_IN
        domains_NNS for_IN the_DT three_CD steps_NNS in_IN the_DT reductive_JJ cycle_NN ._.
        The_DT model_NN arose_VBD from_IN the_DT gene_NN sequence_NN ,_, but_CC was_VBD rapidly_RB tested_VBN by_IN mutating_VBG individual_JJ
        domains_NNS or_CC adding_VBG or_CC deleting_VBG whole_JJ modules_NNS and_CC by_IN observing_VBG predicted_VBN changes_NNS in_IN the_DT
        polyketide_NN product_NN ._. Soon_RB ,_, dozens_NNS of_IN engineered_VBN compounds_NNS had_VBD been_VBN made_VBN ,_, and_CC the_DT field_NN
        mushroomed_VBD with_IN the_DT isolation_NN of_IN more_JJR and_CC more_JJR clusters_NNS of_IN genes_NNS for_IN complex_JJ polyketides_NNS
        that_IN both_DT proved_VBN the_DT generality_NN of_IN the_DT model_NN (_( with_IN minor_JJ variations_NNS )_) and_CC filled_VBD the_DT need_NN
        for_IN spare_JJ parts_NNS for_IN the_DT engineering_NN of_IN countless_JJ new_JJ polyketides_NNS (_( Shen_NNP 2003_CD )_) ._. Several_JJ
        biotech_JJ companies_NNS were_VBD founded_VBN to_TO exploit_VB the_DT potential_NN for_IN drug_NN discovery_NN ._.
      
      
        Aromatic_NNP PKS_NNP Programming_NN
        Meanwhile_RB ,_, the_DT programming_NN of_IN the_DT aromatic_JJ PKSs_NNP was_VBD harder_RBR to_TO understand_VB ._. They_PRP had_VBD been_VBN
        found_VBN to_TO contain_VB only_RB a_DT single_JJ ketosynthase_NN ,_, which_WDT has_VBZ to_TO operate_VB a_DT specific_JJ number_NN of_IN
        times_NNS to_TO build_VB a_DT carbon_NN chain_NN of_IN the_DT correct_JJ length_NN ,_, so_RB how_WRB is_VBZ this_DT determined_JJ ?_. How_WRB does_VBZ a_DT
        single_VB reductive_JJ enzyme_NN know_VB which_WDT keto_NN groups_NNS to_TO modify_VB ?_. And_CC how_WRB is_VBZ the_DT starter_JJ unit_NN for_IN
        building_VBG the_DT carbon_NN chain_NN selected_VBN (_( the_DT extender_NN units_NNS are_VBP normally_RB all_DT malonyl-_NN CoA_NNP ,_, so_IN no_DT
        choice_NN is_VBZ involved_VBN )_) ?_. Considerable_NNP progress_NN had_VBD been_VBN made_VBN in_IN constructing_VBG novel_NN compounds_NNS by_IN
        mixing_VBG and_CC matching_VBG PKS_NNP subunits_NNS ,_, but_CC this_DT was_VBD largely_RB based_VBN on_IN empirical_JJ knowledge_NN about_IN
        which_WDT components_NNS to_TO put_VB together_RB (_( McDaniel_NNP et_CC al_NN ._. 1995_CD )_) ._. A_DT specific_JJ subunit_NN of_IN the_DT PKS_NNP ,_,
        named_VBD the_DT chain_NN length_NN factor_NN (_( CLF_NNP )_) ,_, was_VBD deduced_JJ to_TO have_VB a_DT major_JJ influence_NN on_IN carbon_NN chain_NN
        length_NN (_( McDaniel_NNP et_CC al_NN ._. 1993_CD )_) ,_, but_CC this_DT conclusion_NN was_VBD not_RB universally_RB accepted_VBD in_IN the_DT
        absence_NN of_IN experimental_JJ evidence_NN on_IN its_PRP$ mode_NN of_IN action_NN ._. Two_CD recent_JJ publications_NNS by_IN the_DT
        Khosla_NNP laboratory_NN at_IN Stanford_NNP University_NNP describe_VB significant_JJ advances_NNS in_IN understanding_NN
        aromatic_JJ PKS_NNP programming_NN and_CC promise_NN to_TO turn_VB the_DT spotlight_NN back_RB onto_IN engineered_VBN members_NNS of_IN
        this_DT class_NN of_IN compounds_NNS as_IN potential_JJ drug_NN candidates_NNS by_IN allowing_VBG rational_JJ manipulation_NN of_IN
        the_DT two_CD key_JJ variables_NNS :_: carbon_NN chain_NN length_NN and_CC choice_NN of_IN starter_JJ unit_NN ._.
        In_IN the_DT first_JJ paper_NN (_( Tang_NNP et_CC al_NN ._. 2003_CD )_) ,_, the_DT authors_NNS explore_VBP the_DT hypothesis_NNS that_IN the_DT CLF_NNP
        exerts_NNS control_VBP over_IN carbon_NN chain_NN length_NN by_IN associating_VBG closely_RB with_IN the_DT ketosynthase_NN ,_, a_DT
        protein_NN with_IN which_WDT it_PRP shares_VBZ considerable_JJ amino_JJ acid_NN sequence_NN similarity_NN ,_, giving_VBG rise_NN to_TO a_DT
        channel_NN of_IN a_DT certain_JJ size_NN at_IN the_DT interface_NN between_IN the_DT two_CD proteins_NNS ._. By_IN systematically_RB
        changing_VBG amino_JJ acids_NNS at_IN four_CD key_JJ positions_NNS in_IN the_DT CLF_NNP ,_, the_DT size_NN of_IN the_DT channel_NN was_VBD altered_VBN ._.
        Thus_RB ,_, large_JJ amino_JJ acid_NN residues_NNS in_IN the_DT CLF_NNP of_IN a_DT PKS_NNP that_WDT makes_VBZ a_DT 16_CD -_: carbon_NN chain_NN were_VBD
        replaced_VBN by_IN less_RBR bulky_JJ residues_NNS found_VBD in_IN one_CD that_WDT builds_VBZ a_DT 20_CD -_: carbon_NN chain_NN ,_, and_CC the_DT chain_NN
        length_NN of_IN the_DT product_NN increased_VBD as_IN expected_VBN ._. The_DT authors_NNS propose_VBP that_IN the_DT length_NN of_IN the_DT
        channel_NN is_VBZ the_DT main_JJ factor_NN in_IN controlling_VBG the_DT number_NN of_IN chain-extension_JJ steps_NNS that_WDT can_MD take_VB
        place_NN to_TO fill_VB it_PRP ._. While_IN protein–protein_NN interactions_NNS with_IN other_JJ PKS_NNP subunits_NNS may_MD modulate_VBP
        this_DT chain_NN length_NN control_NN ,_, the_DT work_NN represents_VBZ a_DT major_JJ step_NN in_IN understanding_NN and_CC
        manipulating_VBG the_DT chain_NN length_NN of_IN aromatic_JJ polyketides_NNS ._.
        What_WP about_IN the_DT choice_NN of_IN starter_JJ unit_NN ?_. Most_JJS aromatic_JJ polyketides_NNS start_VBP with_IN acetyl-_NN CoA_NNP ._.
        An_DT important_JJ earlier_JJR publication_NN by_IN Leadlay_NNP and_CC colleagues_NNS (_( Bisang_NNP et_CC al_NN ._. 1999_CD )_) had_VBD shown_VBN
        that_IN this_DT is_VBZ not_RB loaded_VBN directly_RB onto_IN the_DT PKS_NNP ,_, as_IN had_VBD been_VBN assumed_VBN ,_, but_CC is_VBZ derived_VBN by_IN loss_NN
        of_IN carbon_NN dioxide_NN from_IN a_DT molecule_NN of_IN malonyl-_NN CoA_NNP previously_RB loaded_VBD onto_IN the_DT enzyme_NN ._. This_DT
        decarboxylation_NN is_VBZ catalysed_JJ by_IN the_DT CLF_NNP as_IN an_DT activity_NN independent_JJ of_IN its_PRP$ role_NN in_IN
        influencing_VBG carbon_NN chain_NN length_NN ._. There_EX are_VBP ,_, however_RB ,_, certain_JJ aromatic_JJ polyketides_NNS ,_,
        including_VBG the_DT anticancer_NN drug_NN doxorubicin_NN ,_, an_DT antiparasitic_JJ agent_NN called_VBN frenolicin_NN ,_, and_CC
        the_DT estrogen_NN receptor_NN agonist_NN R_NN 1128_CD ,_, that_WDT have_VBP different_JJ starters_NNS ._.
        What_WP Tang_NNP et_CC al_NN ._. (_( 2004_CD )_) have_VBP deduced_JJ ,_, as_IN described_VBN in_IN this_DT issue_NN of_IN 
        PloS_NNP Biology_NNP ,_, is_VBZ that_IN the_DT PKSs_NNP for_IN these_DT compounds_NNS consist_VBP of_IN two_CD
        modules_NNS of_IN active_JJ sites_NNS ._. The_DT components_NNS of_IN each_DT module_NN are_VBP not_RB activities_NNS carried_VBD on_IN the_DT
        same_JJ protein_NN ,_, as_IN in_IN the_DT PKSs_NNP for_IN the_DT complex_JJ polyketides_NNS ,_, but_CC are_VBP all_DT separate_JJ proteins_NNS ._.
        They_PRP form_VBP functional_JJ modules_NNS nevertheless_RB ._. The_DT newly_RB recognized_VBN modules_NNS in_IN the_DT producers_NNS of_IN
        compounds_NNS that_WDT start_VBP with_IN nonacetate_NN units_NNS have_VBP a_DT dedicated_VBN ACP_NNP and_CC a_DT special_JJ ketosynthase_NN
        that_WDT carries_VBZ out_RP a_DT first_JJ condensation_NN ,_, joining_VBG the_DT unusual_JJ starter_JJ unit_NN to_TO the_DT first_JJ
        malonyl-_NN CoA_NNP extender_NN unit_NN ._. The_DT starter_JJ module_NN then_RB hands_VBZ the_DT resulting_VBG ‘ diketide_NN’ on_IN to_TO the_DT
        second_JJ module_NN (_( first_JJ reducing_VBG it_PRP ,_, if_IN appropriate_JJ ,_, using_VBG reductive_JJ enzymes_NNS ‘ borrowed_VBN’ from_IN
        fatty_NN acid_NN biosynthesis_NNS )_) for_IN typical_JJ extension_NN by_IN successive_JJ condensation_NN with_IN malonyl-_NN CoA_NNP
        units_NNS to_TO complete_VB the_DT chain_NN ._. If_IN the_DT starter_JJ module_NN is_VBZ not_RB present_JJ ,_, the_DT second_JJ module_NN
        defaults_NNS to_TO its_PRP$ typical_JJ habit_NN of_IN decarboxylating_VBG malonyl-_NN CoA_NNP to_TO acetyl-_NN CoA_NNP and_CC starts_VBZ the_DT
        chain_NN with_IN that_DT ._.
        The_DT excitement_NN of_IN the_DT work_NN for_IN biotechnology_NN is_VBZ that_IN it_PRP offers_VBZ the_DT prospect_NN of_IN
        engineering_NN promising_JJ drug_NN candidates_NNS by_IN making_VBG novel_NN combinations_NNS of_IN starter_NN and_CC extender_NN
        modules_NNS and_CC perhaps_RB of_IN feeding_VBG the_DT starter_JJ modules_NNS with_IN a_DT whole_JJ range_NN of_IN unnatural_NN
        substrates_NNS (_( Kalaitzis_NNP et_CC al_NN ._. 2003_CD )_) ._. It_PRP is_VBZ encouraging_VBG that_IN already_RB ,_, in_IN the_DT
        proof-of-principle_JJ studies_NNS reported_VBN by_IN Tang_NNP et_CC al_NN ._. (_( 2004_CD )_) ,_, some_DT products_NNS with_IN improved_VBN in_IN
        vitro_NN antitumor_NN activity_NN were_VBD obtained_VBN ._.
      
    
  
